Over the last few decades, the ability of doctors to successfully treat childhood leukemias has risen dramatically. For the small group of patients that don't respond to initial therapy, figuring out why has become an important research topic.

Cancer cells are extremely versatile and adaptable. They find ways to wiggle out of any attempts to restrain them. Researchers are working with the very mechanism that cancer uses to avoid death to develop a potentially powerful therapy for lymphoma.

Genetic experiments have come a long way from growing peas. A new line of testing created a zebrafish with cells that can glow under certain conditions, which helps scientists figure out what drug is the best at killing cancer cells.

Researchers are always looking for new ways to selectively attack cancers while leaving healthy cells alone, as many of the most common treatments for cancer involve some unfortunate friendly fire.

The link between inflammation and cancer has been used to advertise everything from fish oil to aspirin, but the science behind it can be murky. Some new research may show the mechanism behind the link.

Since the advent of targeted therapies, chronic myeloid leukemia ( CML ) has become easier to treat. And while the drugs usually put people into remission, the disease can return with full fury.

Many genetic changes are involved in any given cancer, but some changes are very important to consider for chemotherapy. Acute Myeloid Leukemia (AML) is an example of a cancer where treatment can vary widely depending on the genetics involved.

Vitamin A derivatives, drugs known as retinoids , have been used successfully to treat certain types of leukemia. Not all forms of the disease respond to them, though. Scientists have discovered that adding another medication may overcome this resistance.

Targeted drugs work by attacking and shutting down the molecular activities that keep cancers thriving and growing. These drugs have saved the lives of thousands of people with cancer. But they don't work in some people.

A long-term risk analysis of Hodgkin lymphoma patients shows that the traditional practice of using radiation together with chemotherapy may be too much, causing more problems without extending life expectancy.